Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Study to Assess the Effect of a Combination of Avastin and Docetaxel and Sequential Chemotherapy on Pathological Response in Patients With Primary Operable HER2 Negative Breast Cancer

NCT00559754 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00559754
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00559754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Study to Assess the Effect of a Combination of Avastin and Docetaxel and Sequential Chemotherapy on Pathological Response in Patients With Primary Operable HER2 Negative Breast Cancer
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2007
Completion date
September 30, 2010
Enrollment
72 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer